Modified Parvovirus Expression Construct for rAAV Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant adeno-associated viruses (rAAVs) face challenges in maximizing transfection efficiency and minimizing immunogenicity, while maintaining optimal transgene expression, due to the need for complex plasmid systems and residual helper virus production.
Innovation Solution
A modified expression construct that includes a modified adenovirus E4 coding region, E2a coding region, and adenovirus VA RNA coding region, along with a parvovirus protein coding region, to provide essential helper functions for rAAV production, reducing the reliance on helper virus infection and simplifying the plasmid-based system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If helper virus infection is used to produce rAAV, then viral replication and packaging functions are activated, but residual helper virus production occurs that can elicit immune responses
Solution Approach 1:
The patent extracts and removes the adenovirus genome from the helper plasmid system, retaining only the essential early region coding sequences (E1A, E1B, E2A, E4, VA RNA) needed for rAAV production. This eliminates the production of residual helper adenovirus while preserving the necessary helper functions for AAV replication and packaging.
Solution Approach 2:
The patent segments the adenovirus genome into functional modules, keeping only the early region coding sequences that provide helper functions (E1A, E1B, E2A, E4, VA RNA) while removing the late region and other non-essential elements. This modular approach maintains productivity while reducing immunogenicity.
2Object-affected harmful factors
If a triple-plasmid system is used to eliminate helper virus infection, then immunogenicity is reduced, but transfection efficiency and AAV production may be compromised
Solution Approach 1:
The patent merges the essential adenovirus helper functions (E1A, E1B, E2A, E4, VA RNA) into a single modified helper plasmid that can be co-transfected with the AAV plasmid. This consolidation maintains all necessary helper functions in one construct, simplifying the system while preserving high transfection efficiency and AAV production.
Solution Approach 2:
The modified helper plasmid serves multiple functions simultaneously: it provides E1A and E1B for viral entry and early gene expression, E2A for DNA replication, E4 for late gene expression and assembly, and VA RNA for immune evasion. This multi-functional design ensures high productivity without requiring separate plasmids for each function.
3Productivity
If plasmid size and ratio are optimized in multiplasmid systems, then transfection efficiency is maximized, but the system remains complex
Solution Approach 1:
The patent extracts and eliminates redundant plasmid components by consolidating all essential helper functions into a single modified helper plasmid. This reduction from multiple separate plasmids to one optimized plasmid simplifies the system while maintaining high transfection efficiency through optimized plasmid design.
Data Source
AI summary
Expression constructs and methods for recombinant parvovirus production are disclosed. In some embodiments, the expression construct encodes (1) adenovirus E4 and E2a proteins, (2) parvovirus proteins necessary for the production of the recombinant parvovirus, and (3) a recombinant parvovirus genome, thus allowing production of the recombinant parvovirus by transfecting a host cell with a single expression construct.